کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3999839 | 1601828 | 2012 | 10 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
تومور شناسی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Chemotherapy with docetaxel remains the standard first-line treatment in patients with castration-resistant prostate cancer (CRPC). To date there is no recommended second-line therapy in case of progression after docetaxel treatment. Knowledge of the molecular and cellular changes that occur during the transition of hormone-native to CRPC is increasing rapidly opening new therapy strategies in CRPC patients. This article will focus on recent available therapy options for patients with progressive CRPC after first-line treatment with docetaxel and highlights promising novel substances that are currently under investigation.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Urologic Oncology: Seminars and Original Investigations - Volume 30, Issue 6, November–December 2012, Pages 762–771
Journal: Urologic Oncology: Seminars and Original Investigations - Volume 30, Issue 6, November–December 2012, Pages 762–771
نویسندگان
Christian Arsov, Christian Winter, Robert Rabenalt, Peter Albers,